In this review, we summarize pivotal clinical trials of ICIs in advanced NSCLC, the therapeutic efficacy of PD-1 or PD-L1 inhibitors, and the mechanisms of PD-L1 upregulation in the context of intrinsic pathways that rely upon specific driver alterations. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.